Virtual Grand Rounds on Innovations in Ig Treatments in CIDP

Statement of Need

Although it is a rare immune-mediated neuropathological condition, chronic inflammatory demyelinating polyneuropathy (CIDP) is associated with significant morbidity and reduced quality of life. The development of new guidelines from the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) on diagnosing and treating CIDP, coupled with recent advancements in immunoglobulin (Ig) targeting therapies, offer health care professionals (HCP) and patients hope. U.S.-based HCPs, working as a part of multidisciplinary teams, will benefit from learning how best to utilize the guidelines from their international colleagues in collaborative care approaches to diagnosing and treating CIDP.

In this CME Outfitters Grand Rounds activity, international expert faculty will guide participants through a discussion of the guideline-recommended tools and measures to facilitate early and accurate diagnosis of CIDP, how to utilize real-world strategies to implement novel Ig-targeted therapies in diverse practice settings, and how to implement collaborative care to improve long-term management of CIDP.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

Incorporate the use of guideline-recommended tools and measures to facilitate the early, accurate diagnosis of CIDP
Utilize real-world strategies to implement novel Ig-targeted therapies in diverse practice settings
Implement collaborative care approaches that improve the detection and optimal, long-term management of CIDP

Financial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

Neurologists, physician associates (PAs), nurse practitioners (NPs), infusion specialists, and nurses

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.0

This activity is designated for 1.00 contact hours.

California Residents: Provider approved by the California Board of Registered Nursing, Provider # CEP 15510, for 1.00 Contact Hours.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

Interprofessional (IPCE) 1.0

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.

Physician Assistants (AAPA): 1.00

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 12/04/2026. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Faculty

Dr. Lewis reports the following financial relationships:

Advisory Board/Consultant/Adjudication Committee: Alexion Pharmaceuticals, Inc.; Amgen Inc.; Annexon, Inc.; argenx; Avilar Therapeutics, Inc.; BioCryst Pharmaceuticals, Inc.; CSL Behring: Dianthus Therapeutics; Grifols; Immunovant, Inc.; Johnson & Johnson; Nervosave Therapeutics; Nuvig Therapeutics, Inc.; Sanofi; Seismic Therapeutic; Takeda Pharmaceutical Company Limited; and TG Therapeutics, Inc. (TGTX)

Other financial or material support: DSMB Boehringer Ingleheim; Cartesian Therapeutics, Inc. (MG); and Intellia Therapeutics, Inc. (TTR)

MAB: GBS Global Biopharma, Inc. – CIDP FI

Royalties: UpToDate

Planner

Luis Querol, MD, PhD reports the following financial relationships:

Advisory Board: Argenx; Sanofi Genzyme; and Takeda Pharmaceutical Company Limited

Consultant: Alnylam Pharmaceuticals, Inc.; Annexon, Inc.; argenx, Avilar Therapeutics, Inc.; CSL Behring; BioCryst Pharmaceuticals, Inc.; Dianthus Therapeutics; LFB, Lycia Therapeutics; Merck & Co., Inc.; Montis Biosciences; Novartis; Nuvig Therapeutics, Inc.; Sanofi Genzyme; and Takeda Pharmaceutical Company Limited

Grants: argenx; Instituto de Salud Carlos III – Ministry of Economy and Innovation (Spain); CIBERER; Fundació La Marató; GBS/CIDP Foundation International; Sanofi and UCB

The following individuals have no financial relationships to disclose:

Rebecca Vargas-Jackson, MD (Peer Reviewer)
Jessica Giddens, DNP, APRN, FPMHNP-BC, RN-BC (Peer Reviewer)
Mary Gleason, PhD, CHCP (Planning Committee)
Estelle Perera (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

GRV-106-120425-20